SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is currently trending as a high-conviction speculative play driven by a billion-dollar colocation contract with Cerebras Systems, positioning it as a key AI infrastructure proxy ahead of the Cerebras IPO. The community is heavily debating the company's growth-focused capital raising strategy versus potential dilution, while retail investors remain focused on the potential for institutional rerating as the company scales its modular data center capacity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an intense rally fueled by structural memory shortages and sustained demand for AI infrastructure, leading to widespread community debate over whether the stock is undergoing a long-term rerating or forming a speculative bubble. Investors are actively discussing the impact of supply bottlenecks, potential production strikes, and the company's role as a critical component supplier in the growing AI hardware ecosystem.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders anticipate potential FDA developments following reports of leadership turmoil at the agency and increased institutional positioning from major firms like Vanguard. The community is actively discussing the stock's significant short interest and potential catalysts, including global expansion and the anticipated filing decision for Anktiva's label expansion.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing increased market volatility and investor interest as the community weighs strong quarterly results, expansion in Matrix-M licensing agreements, and the potential impact of a cruise ship-related Hantavirus outbreak. While some investors are monitoring the Hantavirus news for a potential sector-wide rally, others remain focused on the company's long-term pivot toward an IP-licensing model and ongoing internal pressure regarding executive leadership.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing heightened volatility and increased trading volume as the community reacts to emerging details about an early-stage hantavirus vaccine program. Investors are actively debating the stock's future, balancing potential pandemic-driven upside against broader biotech sector rotations and upcoming clinical data presentations.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing a surge in retail interest and trading volume as investors connect the company's specialized MRAM technology to broader AI infrastructure and defense sector momentum. The community is actively debating the stock's potential for a significant squeeze, with many comparing its low-float setup and emerging relevance in edge AI to the recent parabolic moves seen in larger semiconductor peers.

NovaChargeX Coin (NCX) is an Ethereum-based ERC-20 token connected to NovaChargeX LLC, a clean-energy company developing patented hybrid regenerative power systems designed to deliver continuous, grid-independent electricity. The token serves as the on-chain entry point to the NovaChargeX ecosystem, linking blockchain participants to a real-world infrastructure project focused on supplying 24/7 power to AI data centers, industrial facilities, and other operations that cannot tolerate downtime. NCX is positioned in the real-world asset (RWA) and clean-energy infrastructure category. The parent company has been recognized by the World Future Awards 2025 for Best Hybrid Regenerative Clean Energy System and has received coverage from Al Arabiya English, SolarQuarter, and Reuters. The token contract is deployed on Ethereum mainnet, ownership has been renounced, and a third-party security audit has been completed.

NovaChargeX Coin

NovaChargeX is capturing investor attention by positioning itself at the intersection of clean energy infrastructure, blockchain utility, and real-world asset integration. Community members are actively discussing the project's patented technology and its potential to address growing AI-related power demands while remaining in an early development stage.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is trending as the community debates its utility as a decentralized blockchain data indexing layer integrated with Rezolve AI, while simultaneously reacting to recent exchange listings and the launch of new revenue-sharing pools. Investors remain divided, with many highlighting the project's infrastructure role in powering AI-agent commerce, while others express skepticism and frustration over recent price volatility and token performance.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant volatility and high trading volume as investors debate whether the current price action represents a buying opportunity or a deeper correction. The community is actively discussing its long-term potential, with some traders framing it as a rival to established layer-1 blockchains while others remain cautious due to recent price swings and network performance concerns.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors focus on its Tanbreez project's role in establishing a Western supply chain for rare earth elements, bolstered by recent Greenland government approval and an upcoming virtual investor conference. Community discussion is heavily focused on the company's potential for a short squeeze, given high short interest and expectations for upcoming catalysts like definitive agreements and pilot plant updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four ha...

Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday

Keros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.

Keros Therapeutics (NASDAQ:KROS) Director Purchases $11,700.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime acquired 1,000 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was...

Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was acquired at...

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totaling 1,494,814 shares, a...

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the stock, Marketbeat Ratings...

Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,420.6% in the fourth quarter, according to its most recent Form 13F filing with the...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$12.07
Prev Close	$11.64
Open	$11.60
Dividend Yield	0.00%
50-Day Moving Average	$11.63
Beta	0.89
Avg. Volume	334,025.01
PE Ratio	6.63

52-Week High	$22.55
52-Week Low	$10.42
Market Capitalization	$238.84M
EPS (Annual)	$2.30
Price to Book	0.78
Revenue Per Employee	$3.13M

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KROS News

KROSKeros Therapeutics Inc